IF intratracheally administered chitosan-coated, β-galactopyranoside-capped mesoporous silica nanoparticles (Gal-CS-MSNs) loaded with navitoclax (ABT-263; target dose 5–10 mg/kg lung-deposited equivalent, formulated on an MCM-41 scaffold) are administered to aged (18–20 month) male C57BL/6J mice with established bleomycin-induced pulmonary fibrosis carrying a high burden of accumulated senescent lung fibroblasts,

THEN the following will be observed within 21 days of treatment:

• ≥50% reduction in lung SA-β-gal+ cell burden (histomorphometric quantification)
• ≥40% reduction in lung hydroxyproline content versus vehicle-treated fibrotic controls
• Preservation of circulating platelet counts within ≤20% of young reference values (vs. ≥60% thrombocytopenia with oral navitoclax at 50 mg/kg)
• A lung-to-plasma navitoclax area-under-the-curve (AUC) ratio of ≥5:1 measured by LC-MS/MS at 2h and 24h post-instillation

BECAUSE the following causal chain is engaged:

1. Intratracheal instillation of Gal-CS-MSNs deposits nanoparticles directly into the alveolar and interstitial compartment, bypassing first-pass metabolism and hepatic distribution, thereby compartmentalizing navitoclax within lung tissue and restricting systemic bioavailability — a principle established for chitosan-coated pulmonary nanocarriers that achieve lung-to-plasma ratios far exceeding those of IV or oral routes, as synthesized in the literature review (Pulmonary delivery of MSNs and chitosan nanocarriers consistently achieve lung-to-plasma AUC ratios exceeding 10:1–100:1 in murine models)[https://doi.org/10.15252/emmm.201809355].

2. Chitosan surface coating confers mucoadhesive retention in the airway epithelial lining fluid, exploiting electrostatic interactions between cationic chitosan and negatively charged mucins, preventing rapid mucociliary clearance and extending lung residence time from hours to days — a behavior validated for chitosan-functionalized MSN platforms in respiratory tissue (Chitosan-functionalized MSNs demonstrate enhanced cellular uptake and sustained drug release in lung epithelial cancer models)[https://pmc.ncbi.nlm.nih.gov/articles/PMC12775091/].

3. SA-β-gal overexpressed in the enlarged lysosomes of accumulating senescent fibroblasts specifically cleaves the β-glycosidic bonds of the galacto-oligosaccharide caps, triggering pore opening and intracellular navitoclax release exclusively within SA-β-gal-high senescent cells — mirroring the enzymatic uncapping mechanism demonstrated for GalNPs composed of MCM-41 scaffolds capped with β(1,4)-linked galacto-oligosaccharides, which are internalized by endocytosis, trafficked to lysosomes, and opened by SA-β-gal (GalNPs on MCM-41 scaffolds release payload selectively via SA-β-gal enzymatic hydrolysis in senescent cells)[https://doi.org/10.15252/emmm.201809355].

4. Released navitoclax inhibits Bcl-2 and Bcl-xL within senescent fibroblasts, inducing apoptosis and removing the accumulated populatio...

SENS category: GlycoSENS

Key references: • doi.org/10.15252/emmm.201809355]. • doi.org/10.15252/emmm.201809355], • doi.org/10.15252/emmm.201809355